Back to GetFilings.com



Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 10-Q

     (Mark One)

     
x
 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2004

or

     
o
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                     to                    

Commission File Number: 000-27765


SYMYX TECHNOLOGIES, INC.

(Exact name of registrant as specified in its chapter)
     
Delaware   77-0397908
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)
     
3100 Central Expressway,    
Santa Clara, California   95051
(Address of principal executive offices)   (Zip Code)

(408) 764-2000
(Registrant’s telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and, (2) has been subject to such filing requirements for the past 90 days.
Yes  x  No  o

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).
Yes  x No  o

As of July 29, 2004, Registrant had outstanding 32,111,169 shares of Common Stock, $.001 par value.



 


TABLE OF CONTENTS

             
        PAGE
  Financial Statements:        
 
      1  
 
      2  
 
      3  
 
  Notes to Condensed Consolidated Financial Statements     4  
  Management’s Discussion and Analysis of Financial Condition and Results of Operations     15  
  Quantitative and Qualitative Disclosures About Market Risk     34  
  Controls and Procedures     34  
  Legal Proceedings     35  
  Changes in Securities and Use of Proceeds     35  
  Defaults Upon Senior Securities     35  
  Submission of Matters to a Vote of Security Holders     35  
  Other Information     35  
  Exhibits and Reports on Form 8-K     36  
 
 
Signatures
    37  
 
 
Exhibit Index
    38  
 EXHIBIT 31.1
 EXHIBIT 31.2
 EXHIBIT 32.1

 


Table of Contents

PART I: FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SYMYX TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)

                                 
    Three Months Ended   Six Months Ended
    June 30,
  June 30,
    2004
  2003
  2004
  2003
Revenue:
                               
Service revenue from research collaborations
  $ 10,029     $ 8,486     $ 20,490     $ 17,098  
Service revenue — related party
    375       435       1,161       435  
Product sales
    5,467       3,634       10,364       8,627  
License fees and royalties
    3,045       2,442       6,380       3,696  
 
   
 
     
 
     
 
     
 
 
Total revenue
    18,916       14,997       38,395       29,856  
 
   
 
     
 
     
 
     
 
 
Operating expenses:
                               
Cost of products sold
    1,940       800       3,618       1,878  
Research and development
    10,047       9,713       20,103       19,093  
Research and development — related party
    375       435       1,161       435  
Sales, general and administrative
    4,311       3,579       8,422       7,371  
 
   
 
     
 
     
 
     
 
 
Total operating expenses
    16,673       14,527       33,304       28,777  
 
   
 
     
 
     
 
     
 
 
Income from operations
    2,243       470       5,091       1,079  
Interest and other income (expense), net
    716       487       1,235       1,067  
 
   
 
     
 
     
 
     
 
 
Income before income tax expense
    2,959       957       6,326       2,146  
Income tax expense
    1,247       339       2,607       815  
 
   
 
     
 
     
 
     
 
 
Net income
  $ 1,712     $ 618     $ 3,719     $ 1,331  
 
   
 
     
 
     
 
     
 
 
Basic net income per share
  $ 0.05     $ 0.02     $ 0.12     $ 0.04  
 
   
 
     
 
     
 
     
 
 
Diluted net income per share
  $ 0.05     $ 0.02     $ 0.11     $ 0.04  
 
   
 
     
 
     
 
     
 
 
Shares used in computing basic net income per share
    32,040       31,020       31,919       30,972  
 
   
 
     
 
     
 
     
 
 
Shares used in computing diluted net income per share
    33,882       32,113       33,865       31,863  
 
   
 
     
 
     
 
     
 
 

See accompanying notes to condensed consolidated financial statements

1


Table of Contents

SYMYX TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share information)

                 
    June 30,   December 31,
    2004
  2003
    (Unaudited)   (Note 1)
ASSETS
               
Current assets:
               
Cash and cash equivalents
  $ 18,985     $ 17,110  
Available-for-sale securities
    127,909       121,588  
Accounts receivable
    5,432       2,617  
Inventories
    2,732       3,743  
Receivable from related party
    95        
Interest receivable and other current assets
    3,822       4,194  
 
   
 
     
 
 
Total current assets
    158,975       149,252  
Property, plant and equipment, net
    24,321       25,681  
Deferred tax assets and other assets
    2,522       2,603  
 
   
 
     
 
 
Total assets
  $ 185,818     $ 177,536  
 
   
 
     
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
Current liabilities:
               
Accounts payable and other accrued liabilities
  $ 4,825     $ 4,643  
Accrued compensation and employee benefits
    2,568       2,142  
Advance from related party
          137  
Income taxes payable
    3,419       1,055  
Deferred rent
    721       681  
Deferred revenue
    2,917       7,640  
Warranty expense accrual
    1,837       1,800  
 
   
 
     
 
 
Total current liabilities
    16,287       18,098  
 
   
 
     
 
 
Commitments
               
Stockholders’ equity:
               
Preferred stock, $0.001 par value, 10,000,000 shares authorized, issuable in series; no shares issued and outstanding
           
Common stock, $0.001 par value, 60,000,000 shares authorized and 32,095,362 and 31,610,108 shares issued and outstanding at June 30, 2004 and December 31, 2003, respectively
    32       32  
Additional paid-in capital
    168,770       162,160  
Stockholder notes receivable
          (134 )
Deferred stock compensation
          (7 )
Accumulated other comprehensive income (loss)
    (346 )     31  
Retained earnings (accumulated deficit)
    1,075       (2,644 )
 
   
 
     
 
 
Total stockholders’ equity
    169,531       159,438  
 
   
 
     
 
 
Total liabilities and stockholders’ equity
  $ 185,818     $ 177,536  
 
   
 
     
 
 

See accompanying notes to condensed consolidated financial statements

2


Table of Contents

SYMYX TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)

                 
    Six Months Ended
    June 30,
    2004
  2003
Operating activities
               
Net income
  $ 3,719     $ 1,331  
Adjustments to reconcile net income to net cash provided by operating activities:
               
Depreciation and amortization
    6,806       5,942  
Stock-based compensation
    147       25  
Gain on sale of fixed assets
    (155 )      
Changes in assets and liabilities:
               
Accounts receivable
    (2,815 )     3,436  
Inventories
    1,011       (1,229 )
Receivable from related party
    (95 )      
Interest receivable and other current assets
    372       193  
Other long-term assets
    (10 )     101  
Accounts payable and other accrued liabilities
    182       946  
Accrued compensation and employee benefits
    426       106  
Advance from related party
    (137 )      
Income taxes payable
    2,606       1,238  
Deferred rent
    40       64  
Deferred revenue
    (4,723 )     1,198  
Warranty expense accrual
    37       137  
 
   
 
     
 
 
Net cash provided by operating activities
    7,411       13,488  
 
   
 
     
 
 
Investing activities
               
Purchase of property and equipment, net
    (2,535 )     (6,523 )
Purchase of available-for-sale securities
    (54,409 )     (65,614 )
Proceeds from maturities of available-for-sale securities
    44,818       44,915  
Acquisition of technology
          (65 )
 
   
 
     
 
 
Net cash used in investing activities
    (12,126 )     (27,287 )
 
   
 
     
 
 
Financing activities
               
Proceeds from issuance of common stock, net of repurchases
    6,470       1,287  
Repayment of shareholder note receivable
    134        
 
   
 
     
 
 
Net cash provided by financing activities
    6,604       1,287  
 
   
 
     
 
 
Effect of foreign exchange rate changes on cash and cash equivalents
    (14 )     (2 )
 
   
 
     
 
 
Net increase (decrease) in cash and cash equivalents
    1,875       (12,514 )
Cash and cash equivalents at beginning of period
    17,110       25,629  
 
   
 
     
 
 
Cash and cash equivalents at end of period
  $ 18,985     $ 13,115  
 
   
 
     
 
 
Supplemental disclosure of cash flow information
               
Income taxes paid (refunded)
  $ 4     $ (446 )
 
   
 
     
 
 

See accompanying notes to condensed consolidated financial statements

3


Table of Contents

SYMYX TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Summary of Significant Accounting Policies

Business and Basis of Presentation

     Symyx Technologies, Inc. (the “Company” or “Symyx”) develops and applies high-throughput experimentation to the discovery of innovative materials for the chemical, life science, electronics, consumer goods and automotive industries. Symyx works with companies seeking to transform their search for better products and processes through research collaborations, Discovery Tools® sales, and license of materials, intellectual property, and software.

     Symyx® was incorporated in California on September 20, 1994 and completed a reincorporation in the state of Delaware in February 1999. Symyx’s headquarters and mailing address is 3100 Central Expressway, Santa Clara, California, 95051, and the telephone number at that location is (408) 764-2000. Our SEC filings are available free of charge through our website at www.symyx.com. Our common stock trades on the Nasdaq National Market under the symbol “SMMX”.

     The accompanying unaudited condensed consolidated financial information has been prepared by management, in accordance with generally accepted accounting principles for interim financial information and pursuant to instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to the Securities and Exchange Commission’s rules and regulations. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position at June 30, 2004 and results of operations and cash flows for all periods presented have been made. The consolidated condensed balance sheet at December 31, 2003 has been derived from the audited financial statements at that date.

     These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements as included in the Company’s 2003 Annual Report on Form 10-K as filed with the Securities and Exchange Commission. The results of operations for the three and six months ended June 30, 2004 are not necessarily indicative of the results to be expected for any subsequent quarter or for the entire fiscal year ending December 31, 2004.

Principles of consolidation

     These condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Symyx Technologies AG, incorporated in Switzerland and Symyx Discovery Tools, Inc., incorporated in California. All significant inter-company balances and transactions have been eliminated on consolidation.

Reclassifications

     Certain reclassifications have been made to prior period amounts to conform to the current period presentations. Segment revenue for prior periods has been reclassified to conform to the current period presentations. Amounts received from a related party reported as accounts payable and deferred revenue in the previous period have been reclassified as advance from related party.

Use of Estimates

     The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to exercise judgment in making estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from these estimates.

     The actual results with regard to warranty expenditures could entail adjustments to be made to the Company’s financial statements if system failures or the cost to repair systems differ from what the Company has used in estimating the warranty expense accrual.

4


Table of Contents

SYMYX TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Revenue Recognition

     The Company generates revenue from services provided under research collaborations, the sale of products, licensing of software, provision of support and maintenance services and the license of intellectual property. It is possible for our customers to work with us in multiple areas of our business and contracts may include multiple elements of service revenue, product revenue and license revenue. In determining the basis for revenue recognition, the Company first determines the fair value of any extended warranty services and defers this revenue to be recognized over the service period. For those contracts that involve multiple element deliverables, the Company identifies all deliverables, determines the units of accounting and allocates revenue between the units of accounting in accordance with the Emerging Issues Task Force consensus on Issue 00-21, “Multiple-Deliverable Revenue Arrangements.” (“EITF 00-21”).

     Service Revenue

     The Company recognizes service revenue from research collaboration agreements and support and maintenance agreements as earned based upon the performance requirements of the agreements. Payments received prior to performance are deferred and recognized as revenue when earned over future performance periods. Collaboration agreements generally specify minimum levels of research effort required to be performed by the Company. Payments received under research collaboration agreements are not refundable if the research is not successful. Direct costs associated with these contracts are reported as research and development expense.

     Non-refundable, up-front payments received in connection with research and development collaboration agreements, including technology access fees, are deferred and recognized on a straight-line basis over the relevant periods specified in the agreement (generally the research term). Revenue from milestone payments, which are substantially at risk until the milestones are completed, is recognized upon completion of these milestone events. Because the Company’s service agreements are not typically structured in milestones, milestone payments to date have been immaterial.

     Product Sales

     Product sales revenue includes sales of Discovery Tools hardware and the license of associated software. The Company’s Discovery Tools systems are typically delivered under multi-element arrangements, which include hardware, software and intellectual property licenses, and maintenance. A determination is made for each system delivered as to whether software is incidental to the system as a whole. If software is not incidental to the Discovery Tools system as a whole, revenue from these arrangements is recognized in accordance with American Institute of Certified Public Accountants Statement of Position 97-2, Software Revenue Recognition (“SOP 97-2”), as amended. If software is incidental to the Discovery Tools system, revenue from the sale of the Discovery Tools system is earned and recognized when persuasive evidence of an arrangement exists, delivery of the product has occurred, no significant obligations with regard to implementation remain, the fee is fixed or determinable, and collectibility is probable. This is generally upon shipment, transfer of title to and acceptance by the customer of the hardware and associated software and licenses to intellectual property, unless there are extended payment terms. The Company considers all arrangements with payment terms extending beyond 12 months not to be fixed or determinable. If the fee is not fixed or determinable, revenue is recognized as payments become due from the customer. In multiple element arrangements, the Company uses the residual method to allocate revenue to delivered elements once it has established fair value for all undelivered elements. Payments received in advance under these arrangements are recorded as deferred revenue until earned.

     An accrual is established for warranty expenses at the time the associated revenue is recognized. Shipping and insurance costs associated with the sale of discovery tools systems are not material and are included in sales, general and administrative costs.

5


Table of Contents

SYMYX TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

     Software License Fees

     Amounts received from third parties for licenses to the Company’s software are recognized when earned under the terms of the agreements. For software licensed on an annual right to use basis, the revenue is recognized straight line over the term of the license. For revenue allocable to the software portion of a multiple element arrangement or licensed on a perpetual basis, the Company recognizes revenue upon delivery of the software product to the end-user and commencement of the license, unless the Company has ongoing obligations for which fair value cannot be established or the fee is not fixed or determinable or collectibility is not probable. The Company considers all arrangements with payment terms longer than twelve months not to be fixed or determinable. If the fee is not fixed or determinable, revenue is recognized as payments become due from the customer, provided all the other revenue recognition criteria have been met. In multiple element arrangements, the Company uses the residual method to allocate revenue to delivered elements once it has established fair value for all undelivered elements.

     Revenue allocable to support and maintenance is recognized on a straight-line basis over the period the support and maintenance is provided. The Company’s product related software licenses may provide for technical support, bug fixes and rights to unspecified upgrades on a when-and-if-available basis for periods defined within the contract. Revenue related to this post contract customer support is deferred and recognized over the term of the contracted support.

     Intellectual Property License Fees and Royalties

     Amounts received from third parties for licenses to the Company’s intellectual property are recognized when earned under the terms of the agreements. Generally revenue is recognized upon transfer of the license unless the Company has continuing obligations for which fair value cannot be established, in which case the revenue is recognized over the period of the obligation. If there are extended payment terms, license fee revenue is recognized as these payments become due. The Company considers all arrangements with payment terms extending beyond 12 months not to be fixed or determinable. If there is a provision in the licensing agreement for a variable fee in addition to a non-refundable minimum amount, the amount of the non-refundable minimum guarantee is recognized upon transfer of the license unless the Company has continuing obligations for which fair value cannot be established and the amount of the variable fee in excess of the guaranteed minimum is recognized as revenue when it is fixed and determinable.

     Royalty revenue is recorded based on reported sales by third party licensees of products containing the Company’s software and intellectual property. If there are extended payment terms, royalty revenues are recognized as these payments become due. Non-refundable royalties, for which there are no further performance obligations, are recognized when due under the terms of the agreements.

     Amounts received from third parties for options to license certain technology or enter collaborative arrangements upon specified terms are deferred until either the option is exercised or the option right expires.

6


Table of Contents

SYMYX TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Concentration of Revenue

     For the three and six months ended June 30, 2004 and 2003, the following customers contributed more than 10% of the Company’s total revenue (in thousands):

                                 
    Three Months Ended   Six Months Ended
    June 30,
  June 30,
    2004
  2003
  2004
  2003
ExxonMobil
  $ 9,672     $ 4,869     $ 18,191     $ 7,729  
Merck
    1,485       1,149       2,050       4,888  
North Dakota State University
    1,572       1,578       1,653       2,860  
Pfizer
    61             4,201        
Undisclosed Partner
    834       1,850       1,833       3,583  
 
   
 
     
 
     
 
     
 
 
Total
  $ 13,624     $ 9,446     $ 27,928     $ 19,060  
 
   
 
     
 
     
 
     
 
 

     The 2004 revenue above includes revenue from ExxonMobil for research funding, product sales and license fees under the alliance entered into in July 2003, revenue from development funding and extended maintenance agreements with Merck, revenue from sale of Discovery Tools Systems to North Dakota State University, partial revenue related to the preformulations/polymorph Discovery Tools system and software shipped to Pfizer during the first quarter of 2004, and research funding from an Undisclosed Partner.

     The revenue from the above five customers has been included in the following reportable segments for the three and six months ended June 30, 2004 and 2003 (in thousands):

                                 
    Three Months Ended   Six Months Ended
    June 30,
  June 30,
    2004
  2003
  2004
  2003
Industry Collaborations
  $ 7,188     $ 5,479     $ 14,476     $ 9,329  
Discovery Tools
    5,686       3,217       11,952       8,981  
Intellectual Property Licensing
    750       750       1,500       750  
 
   
 
     
 
     
 
     
 
 
Total
  $ 13,624     $ 9,446     $ 27,928     $ 19,060  
 
   
 
     
 
     
 
     
 
 

     The revenue from the above five customers has been included in the Condensed Consolidated Statements of Operations as follows (in thousands):

                                 
    Three Months Ended   Six Months Ended
    June 30,
  June 30,
    2004
  2003
  2004
  2003
Service revenue from research collaborations
  $ 6,757     $ 5,006     $ 13,554     $ 9,752  
Product sales
    4,058       2,151       8,809       6,945  
License fees and royalties
    2,809       2,289       5,565       2,363  
 
   
 
     
 
     
 
     
 
 
Total
  $ 13,624     $ 9,446     $ 27,928     $ 19,060  
 
   
 
     
 
     
 
     
 
 

7


Table of Contents

SYMYX TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Inventories

     Work in process inventory comprises customized Discovery Tools systems in the process of being built. Finished goods inventory comprises of Discovery Tools systems that have been finished but are pending shipment to customers. Inventories are carried at the lower of cost or market, determined on a specific identification basis. The following table summarizes the components of the Company’s inventory balance (in thousands):

                 
    June 30,   December 31,
    2004
  2003
Work in Process
  $ 2,461     $ 1,960  
Finished Goods
    271       1,783  
 
   
 
     
 
 
Total
  $ 2,732     $ 3,743  
 
   
 
     
 
 

Warranty expense accrual

     The Company offers a warranty on each Discovery Tools System shipped. The specific terms and conditions of these warranties vary depending upon the product sold and country in which the Company does business. However, they typically include coverage for parts and labor and software bug fixes for a specified period (typically one year). The Company estimates the costs that may be incurred under its basic limited warranty and records a liability in the amount of such costs at the time product revenue is recognized. Factors that affect the Company’s warranty liability include the number of installed units, historical and anticipated rates of warranty claims, and cost per claim. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts, as necessary.

     Changes in the Company’s product warranty expense accrual during the six months ended June 30, 2004 are as follows (in thousands):

         
Balance as of December 31, 2003
  $ 1,800  
New warranties issued during the period
    267  
Costs incurred during the period on specific systems
    (90 )
Changes in liability for pre-existing warranties during the period, including expirations
    (140 )
 
   
 
 
Balance as of June 30, 2004
  $ 1,837  
 
   
 
 

Income Taxes

     Income taxes have been provided using the liability method. Deferred tax assets or liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized.

8


Table of Contents

SYMYX TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Stock-Based Compensation

     Compensation expense for options to purchase the Company’s common stock granted to non-employees has been determined in accordance with SFAS 123 and EITF 96-18 as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for options to purchase the Company’s common stock granted to non-employees is periodically re-measured as the underlying options vest.

     The Company generally grants stock options to its employees for a fixed number of shares with an exercise price equal to the fair value of the shares on the date of grant. As allowed under the Statement of Financial Accounting Standards No. 123, “Accounting for Stock-Based Compensation” (“SFAS 123”), the Company has elected to follow Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees” (“APB 25”) and related interpretations in accounting for stock awards to employees. Accordingly, no compensation expense is recognized in the Company’s financial statements in connection with stock options granted to employees with exercise prices not less than fair value. Deferred compensation for options granted to employees is determined as the difference between the deemed fair market value of the Company’s common stock on the date options were granted and the exercise price. For purposes of the pro-forma disclosure, the estimated fair value of the options is assumed to be amortized to expense over the options’ vesting periods.

     Pro forma information under SFAS 123 is as follows (in thousands, except per share data).

                                 
    Three Months Ended   Six Months Ended
    June 30,
  June 30,
    2004
  2003
  2004
  2003
Net income (loss):
                               
As reported
  $ 1,712     $ 618     $ 3,719     $ 1,331  
Add: Stock-based employee compensation expense included in reported net income
    2       23       7       25  
Deduct: Total stock-based employee compensation expense determined under fair value method for all awards, net of related tax effects
    (1,399 )     (3,462 )     (2,922 )     (7,057 )
 
   
 
     
 
     
 
     
 
 
Pro forma net income (loss)
  $ 315     $ (2,821 )   $ 804     $ (5,701 )
 
   
 
     
 
     
 
     
 
 
Basic net income (loss) per share:
                               
As reported
  $ 0.05     $ 0.02     $ 0.12     $ 0.04  
 
   
 
     
 
     
 
     
 
 
Pro forma
  $ 0.01     $ (0.09 )   $ 0.03     $ (0.18 )
 
   
 
     
 
     
 
     
 
 
Diluted net income (loss) per share:
                               
As reported
  $ 0.05     $ 0.02     $ 0.11     $ 0.04  
 
   
 
     
 
     
 
     
 
 
Pro forma
  $ 0.01     $ (0.09 )   $ 0.02     $ (0.18 )
 
   
 
     
 
     
 
     
 
 

9


Table of Contents

SYMYX TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

     The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:

                                 
            Stock Option Plans        
    Three Months Ended   Six Months Ended
    June 30,
  June 30,
    2004
  2003
  2004
  2003
Expected dividend
    0.0 %     0.0 %     0.0 %     0.0 %
Risk-free interest rate
    3.3 %     2.2 %     2.8 %     2.2 %
Expected volatility
    61.0 %     68.0 %     67.0 %     68.0 %
Expected life (in years)
    3.5       3.5       3.5       3.5  

     The Black-Scholes option pricing model was developed for use in estimating the value of traded options that have no vesting restrictions and are fully transferable. In addition, option pricing models require the input of highly subjective assumptions including the expected stock price volatility. The Company uses projected data for expected volatility and expected life of its stock options based upon historical and other economic data trended into future years. Because the Company’s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the estimate, in management’s opinion, the existing valuation models do not provide a reliable measure of the fair value of the Company’s employee stock options. Under the Black-Scholes option pricing model, the weighted-average estimated fair values of employee stock options granted during the three and six months ended June 30, 2004 were $11.36 and $12.14 per share, respectively, and for the three and six months ended June 30, 2003 were $7.92 and $7.11 per share, respectively.

     The fair value of shares of common stock relating to the Employee Stock Purchase Plan is estimated on the issuance date using the Black-Scholes model and the following weighted average assumptions for issuances made in 2004 and 2003:

                     </